The required dose of the oral anticoagulant warfarin varies greatly, and overdosing often leads to bleeding. Warfarin is metabolised by cytochrome P450 enzymes CYP2C9, CYP1A2 and CYP3A. The target cell level of warfarin may be dependent on the efflux pump P-glycoprotein, encoded by the adenosine triphosphate-binding cassette gene ABCB1 (multidrug resistance gene 1). Genetic variability in CYP2C9, CYP3A5 and ABCB1 was analysed in 201 stable warfarin-treated patients using solid-phase minisequencing, pyrosequencing and SNaPshot. CYP2C9 variants, age, weight, concurrent drug treatment and indication for treatment significantly influenced warfarin dosing in these patients, explaining 29% of the variation in dose. CYP3A5 did not affect warfarin dosing. An ABCB1 haplotype containing the exon 26 3435T variant was over-represented among low-dose patients. Thirty-six patients with serious bleeding complications had higher prothrombin time international normalised ratios than 189 warfarin-treated patients without serious bleeding, but there were no significant differences in CYP2C9, CYP3A5 or ABCB1 genotypes and allelic variants.
INTRODUCTION
Nearly 1% of the Swedish population is treated with the oral anticoagulant warfarin. The indications for treatment include atrial fibrillation, heart valve prosthesis, recurrent stroke, deep vein thrombosis and pulmonary embolism. 1 Interindividual variation in the response to warfarin and a narrow therapeutic range are two of the factors that make warfarin therapy difficult to handle. In all, bleeding complication during treatment with warfarin is the most common adverse drug reaction with a fatal or disabling outcome. 2, 3 Warfarin is a coumarin derivative that interferes with the recycling of vitamin K in the liver. 2 Vitamin K is involved in the carboxylation of the precursor proteins for the coagulation factors II, VII, IX and X. In the presence of warfarin, the activity of these components in the blood is lowered by around 10-40% and coagulation is inhibited. 3, 4 The effect is delayed until dysfunctional coagulation factors have been synthesised, which takes 4-5 days. 4 Patients treated with warfarin are monitored by prothrombin time (PT) expressed as an international normalised ratio (INR) . PT INR measures the sum of activity of the vitamin Kdependent coagulation factors II, VII and X. For most indications, the ideal PT INR value lies between 2.0 and 3.0. [4] [5] [6] One exception is heart valve prosthesis, which requires a higher PT INR.
The dose requirement of warfarin varies more than 10-fold between patients. 7 In general, women need lower doses than men. 4 A high dietary intake of vitamin K leads to a higher dose requirement, while old age is associated with lower doses. [8] [9] [10] [11] Diseases that increase the sensitivity to warfarin include liver dysfunction impairing the synthesis of coagulation proteins, hypermetabolic states that increase the clearance of coagulation factors and congestive heart failure that alters the distribution of warfarin. 3, 6, 11 Warfarin is highly bound to serum albumin, which in combination with its extensive cytochrome P450 (CYP) metabolism and narrow therapeutic range makes warfarin susceptible to drug interactions. 12 An asymmetric carbon in the warfarin molecule gives rise to the enantiomeric forms S-and R-warfarin. 13 Both enantiomers are eliminated extensively via hepatic metabolism with a low extraction ratio. The S-form is a 3-5 times more potent vitamin K antagonist than the R-form. 6, 7 CYP2C9 is the main enzyme responsible for metabolism of the active S-warfarin, 7, 13 which renders the genetic variation of this metabolic pathway extremely important.
14 In addition to the CYP2C9*1 wild-type allele, at least 11 variant alleles are known to exist (http://www.imm.ki.se/ cypalleles/ in September 2003). The most common variants CYP2C9*2 (430C4T, R144C) and CYP2C9*3 (1075A4C, I359L) generate enzymes with impaired hydroxylation of S-warfarin due to amino-acid changes, and several studies have shown that these variants have an effect on warfarin dose requirement. 7, 11, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] R-warfarin is mainly metabolised by the CYP enzymes CYP1A2 and CYP3A, with CYP3A likely to be the most important.
13 CYP3A activity is derived from CYP3A4 and CYP3A5 that have similar substrate specificities. CYP3A5 is considered to be 17-50% of the total CYP3A content in the livers of people that express it. 25, 26 There is considerable intra-and interindividual variation in CYP3A4 enzyme activity, and even though numerous polymorphisms have been found, the molecular basis of this is not yet understood. On the other hand, CYP3A5 exists in distinct fast and slow variants, 25 and is therefore worth studying even if it is less abundant than CYP3A4. CYP3A5*1 encodes an active enzyme, whereas CYP3A5*3 (6986A4G) and CYP3A5*6 (14690G4A) are inactive due to splicing defects. The CYP3A5*3 allele is the most common cause of low CYP3A5 functionality in Caucasians, while CYP3A5*6 is rarely found.
There is preliminary evidence that P-glycoprotein (P-GP) contributes to warfarin disposition. 27 P-GP belongs to a class of adenosine triphosphate-binding cassette (ABC) transport proteins. 28 It serves as a potent efflux pump for a wide variety of lipophilic compounds that are frequently CYP3A substrates.
29 P-GP is expressed in tissues such as the intestine, liver, kidney, blood-brain barrier and placenta. 28 Warfarin is well absorbed from the intestine with over 90% bioavailability, making it unlikely that intestinal P-GP affects the absorption of warfarin to a great extent. 1 After absorption, the target of warfarin action is the liver, where it inhibits vitamin K epoxide reductase. 2 Warfarin has been shown to be a moderate inhibitor of P-GP activity in human hepatocytes, which indicates that warfarin is a P-GP substrate in the liver. 27 In theory, low P-GP activity in hepatocytes may lead to a high level of warfarin in the target cell, causing warfarin sensitivity in some people.
The ABCB1 gene, also called the multidrug resistance gene 1 (MDR1), encodes P-GP. There are many known polymorphisms in ABCB1: for example, À12T4C in exon 1 in the 5 0 untranslated region, À1G4A at the initiation of translation in exon 2, 1199G4A in exon 11 leading to amino-acid change S400N, 1236C4T in exon 12 at a wobble position G412G, 2677G4T or G4A in exon 21 leading to A893S or T, and in exon 26 two polymorphisms at wobble positions, 3396C4T A1132A and 3435C4T I1145I. 28, 30 Polymorphisms of ABCB1 are suggested to be important for variability in drug bioavailability, but the pharmacological implication of these polymorphisms has not been fully established. 30 Haemorrhage is the most common adverse reaction to coumarin anticoagulants, and a great under-reporting of these events is believed to exist. 3, 31 Swedish studies have shown that 4.5% of warfarin-treated patients experience major bleeding and 0.5% suffer fatal complications. 31 The risk of bleeding is 10 times higher during the first month compared to after the first year. 5 There is a clear relationship between haemorrhage and the intensity of treatment, with PT INR elevation being a strong predictor. 3, 5, 10, 32 Age, concurrent medication, specific comorbid conditions, especially cerebrovascular, kidney, heart and liver disease as well as prosthetic heart valves, are independent risk factors. 5, 32 Several studies suggest that patients with CYP2C9 variant alleles have a higher incidence of bleeding complications than carriers of the wild-type genotype. 15, 16, 20, 22 The risk of haemorrhage must always be weighed against the prevention of thromboembolism, and in most patients the preventive effect outweighs the risk of bleeding. 4, 32 The aim of the study was to identify factors that influence the effect of warfarin and the required dose. Warfarin dose requirement was compared to genetic variation of CYP2C9, CYP3A5 and ABCB1, age, gender, weight, smoking, indication for treatment, and concurrent medication. In the casecontrol part, we studied these factors in relation to warfarin bleeding.
RESULTS

Dose Requirement
The first aim was to identify factors that influence the required dose of warfarin. The patients were recruited in 2000, when they were 28-88 years old (Table 1) . They had stable PT values, and had been treated with warfarin for between 2.4 months and 26 years (median 2 years). Individual warfarin dose requirement varied between 4.5 and 77.25 mg per week. The most frequent indications for anticoagulation were atrial fibrillation, heart valve prosthesis and deep vein thrombosis/pulmonary embolism. The most common concomitant diseases were hypertension, heart failure, angina pectoris and type II diabetes mellitus. The patients had a total of 107 concurrent medications known to influence warfarin, the most common being simvastatin, aspirin, paracetamol, amiodarone, disopyramide and dextropropoxyphene. Four patients were treated with medicines that lower the effect of warfarin by inducing its metabolism, while 74 were treated with medications that potentiate its effect. When the medical records were examined in 2002, we found that 12 of the patients (6.0%) had suffered serious warfarin bleeding since the start of therapy, and 41 (20.4%) had reported minor bleeding, mainly nose bleeding (19.5%).
Two-thirds of the 201 patients carried the CYP2C9*1/*1 genotype. Patient characteristics were similar in carriers of the CYP2C9*1/*1 genotype and carriers of other CYP2C9 genotypes (Table 1) . CYP2C9, CYP3A5 and ABCB1 allele and genotype frequencies were calculated (Table 2 ). In all, 2% of the individuals were predicted to be CYP2C9 poor metabolisers, that is, were genotyped CYP2C9*2/*2, *2/*3 or *3/*3. According to genotyping, 12% had an active CYP3A5 enzyme, that is, were genotyped CYP3A5*1/*1 or *1/*3. No CYP3A5*6 alleles were detected.
Analysis of covariance was performed to see which of the factors, CYP2C9, CYP3A5, ABCB1, age, gender, bodyweight (BW), smoking habits, mean PT INR value, concurrent drug treatment and indication for treatment, have a significant effect on mean warfarin dose and dose/BW. The following factors were significantly related to warfarin dose and dose/ BW according to the generalised linear models (GLM) procedure in SAS: CYP2C9 genotype, age, weight, concurrent drug treatment and indication for treatment (Table 3) . These factors together explain approximately 29% of the variation in warfarin doses (R 2 E0.29). Least-squares means (LS means) for the effects in the model with adjustment for multiple comparisons were computed to describe how the variables affect dose (Table 4) . Patients with the CYP2C9*1/ *1 genotype had the highest mean weekly dose of warfarin ( Figure 1 ). This group had significantly higher doses than patients with the genotypes *1/*3 and *2/*2, *2/*3 or *3/*3. Patients carrying CYP2C9*1/*2 also differed significantly from predicted poor metabolisers. The findings were similar for warfarin dose/BW (Tables 3 and 4 ). Patients treated with Comparisons between patients with the CYP2C9*1/*1 genotype (n ¼ 134) and other CYP2C9 genotypes (n ¼ 67). A patient can have more than one indication, concurrent disease and interacting medication, and only the most common ones are shown. Drugs potentiating the effect of warfarin are indicated by s and drugs decreasing its effect by r Warfarin related to CYP2C9, CYP3A5 and ABCB1 (MDR1)
warfarin because of heart valve prosthesis had significantly higher doses and doses/BW than other patients. Warfarin doses were significantly increased by interaction with drugs that induce warfarin metabolism, and younger patients tended to have higher doses than older patients. Patients were divided into three equally sized dose/BW groups (33% in each group) to test for an association with CYP2C9 and CYP3A5 genotypes. The distribution over low, medium and high dose/BW differed markedly between patients with the CYP2C91*/1* genotype: 27.6% low, 29.8% medium and 42.5% high, compared with patients with other CYP2C9 genotypes: 44.8% low, 40.3% medium and 14.9% high (w 2 , 2 df, P ¼ 0.0004). No association between CYP3A5 allelic variants and dose/BW was found.
ABCB1 haplotypes were predicted based on seven variable sites and their frequencies calculated (Table 5 ). The ABCB1 D haplotype occurred significantly more often than expected in the low-dose/BW group: 60% low, 25% medium and 15% high (w 2 , 2 df, P ¼ 0.0242, Table 5 ). There were no patients homozygous for the D haplotype. The 20 patients, who were heterozygous for the D haplotype, had on an average 24% lower warfarin dose and dose/BW compared to the 181 patients who did not carry the D haplotype. Genotyping of CYP3A5 and ABCB1 Exon 1 failed in two patients.
Warfarin related to CYP2C9, CYP3A5 and ABCB1 (MDR1)
In conclusion, CYP2C9 genotype, age, weight, concurrent drug treatment and indication for treatment all significantly influenced warfarin dosing. One ABCB1 haplotype was associated with a low warfarin dose requirement.
Bleeding Complications
The second aim was to identify risk factors for serious warfarin bleeding requiring hospital care. Cases had been treated with warfarin for 1 week up to 10 years (median: 6.5 months) prior to the bleeding episode. The most common indications for treatment were atrial fibrillation, heart valve prosthesis and deep vein thrombosis/pulmonary embolism. In all, 16 patients had suffered cerebral bleeding, six patients severe nose bleeding, two patients rectal bleeding and the remaining 12 patients had other serious bleeding.
None of the factors CYP2C9, CYP3A5 or ABCB1 (Table 6) , age, gender, indication for treatment or interacting drugs could be identified as a significant risk factor for warfarin bleeding using contingency tables and logistic regression. Prothrombin time was the only factor that differed significantly between cases and controls (mean PT INR 3.56 and 2.58, respectively); logistic regression, Po0.05. The frequency of the indication heart valve prosthesis, which requires a higher target PT INR, was similar among cases (19.4%) and controls (24.3%).
DISCUSSION
Genetic variation of CYP2C9 and its effect on warfarin dosing has rendered great interest over the last few years. 14 CYP2C9 is responsible for the metabolism of the active Swarfarin. Our results corroborate previous studies by finding a significant relationship between the number of functional CYP2C9 alleles and the required maintenance dose of warfarin. The CYP2C9*3 variant inactivates the enzyme more than the CYP2C9*2 variant, which is clearly illustrated The patients were divided into three equally large-dose/BW groups, and the distribution of haplotypes was compared between low-, medium-and high-dose patients. The D haplotype was significantly more common among low-dose patients and less common among high-dose patients than other haplotypes Genotyping of one case failed for ABCB1 polymorphisms in Exon s 11 and 12, and of three cases for Exon 1. Genotyping of two controls failed for ABCB1 polymorphism in Exon 1. There are 36 cases (72 alleles and haplotypes) and 189 controls (378 alleles and haplotypes). Cases have experienced serious warfarin bleeding, while controls have been treated without this side effect. Figure 1 . CYP3A enzymes, with activity derived from both CYP3A5 and CYP3A4, are involved in the metabolism of R-warfarin. 33 Only 12% of the individuals in this study were predicted to express CYP3A5, and there was no indication that CYP3A5 influenced warfarin dosing. This pathway is probably less important for warfarin dosing because R-warfarin is not as potent as S-warfarin, and furthermore CYP3A5 hydroxylates R-warfarin at a lower rate than CYP3A4. 33 The hitherto most studied ABCB1 polymorphism 3435C4T in exon 26 is in itself silent, but there is evidence of linkage disequilibrium extending from at least exons 26 to 12, indicating that the 3435C4T polymorphism may be a marker for other polymorphisms within this block. 34 Individuals homozygous for the 3435T polymorphism have low levels of duodenal P-GP expression and increased bioavailability and higher plasma concentrations of digoxin. 28, 30 There are conflicting results from other studies, possibly explained by their use of different substrates and ethnic groups. 35, 36 Our ABCB1 haplotype frequencies correlate very well with those found in Caucasians in a recent study. 37 We found that patients heterozygous for the ABCB1 haplotype D have a lower warfarin dose requirement than others. This haplotype contains the 3435C4T nucleotide exchange, and no change at the other studied positions. Low P-GP efflux activity in the hepatocyte leading to high levels of warfarin in the target cell could be an explanation as to why patients with the ABCB1 D haplotype appear to be sensitive to warfarin. Owing to the limited number of individuals studied, this could be a chance observation, and a much larger study would be needed to confirm the results.
Warfarin related to CYP2C9, CYP3A5 and ABCB1 (MDR1)
A patient's target PT INR is determined by the indication for warfarin treatment. Patients with heart valve prosthesis have a higher target PT INR, and it was clearly shown that they are given higher warfarin doses. BW is another factor that self-evidently is taken into consideration when prescribing warfarin. Reflecting a decline in bodily functions, elderly patients often need lower doses of medicines, and it was shown that warfarin dose requirement decreased with age. Concurrent medications are extremely important because of the risk of interactions, and care should be taken when changing medication during warfarin therapy. When a new potentially interacting medicine is given to a warfarin patient, the risk of bleeding is well recognised. The highdose requirement in patients on enzyme-inducing drugs is a reminder of the fact that it in some cases, it may be just as important to increase warfarin doses to avoid thrombosis.
Previous studies have shown that about 5% of warfarintreated patients experience major bleeding. 31 Of the 201 patients recruited from the Uppsala University Hospital anticoagulation clinic, 12 (6%) had at some time experienced a serious bleeding requiring hospital care. Thus, the incidence of major bleeding in our study is in good agreement with previously published studies. Significantly higher PT INR values were found in connection with the bleeding. The frequency of heart valve prosthesis, which requires a higher target PT INR, was similar among cases and controls, indicating that the high INR found among cases was not intentional, and may have been caused by accidental overdosing. CYP3A5 and ABCB1 were not identified as risk factors for bleeding complications and in contrast to other studies, neither were CYP2C9 genotypes or alleles. 15, 16, 20, 22 However, the number of cases in this study is small and the results are not conclusive. Owing to the sampling procedure, mainly patients who survived bleeding complications were included in the study, which means that an important group of patients with fatal bleeding was missed.
In summary, our results confirm that CYP2C9 genotyping can identify individuals who are poor metabolisers of warfarin, and hence need lower doses of the drug. Owing to warfarin's narrow therapeutic range and severe side effects, it would be advantageous if individuals requiring extremely low doses of warfarin could be identified before initiating therapy. These patients could be monitored more closely or in the future be offered a novel oral anticoagulant that does not require coagulation monitoring or dose adjustment. 38 Age, weight, indication for treatment and concurrent medication are other important factors that should be taken into consideration when initiating warfarin therapy. The effect of ABCB1 haplotype D on warfarin dosing needs to be further evaluated in a larger study. (Table 4) . To find cases who had experienced serious bleeding episodes requiring hospital care, the 201 patients' medical records were gone through from start of therapy and up to 2002. The exclusion criteria were thrombolysis, surgery or trauma immediately preceding the bleeding. Of the 201 patients, 12 classified as cases. In addition, 24 other patients with serious warfarin bleeding were recruited; 20 through the Swedish spontaneous reporting of adverse drug reactions and four from an ongoing national study on cerebral bleeding and warfarin. 39 In total, 36 cases with serious warfarin bleeding requiring hospital care were included, while the remaining 189 patients at the anticoagulation clinic without serious bleeding were used as controls. The Local Research Ethics Committee approved the study.
MATERIALS AND METHODS
Genotyping
Deoxyribonucleic acid (DNA) was extracted from whole blood using standard procedures. Genotyping was performed by three different methods based on polymerase chain reaction (PCR).
The variants CYP2C9*2 and *3 were identified using solidphase minisequencing. 40 In short, a DNA fragment spanning the variable nucleotide position is amplified using PCR with one biotinylated and one nonbiotinylated PCR primer. The biotinylated fragment is captured on a streptavidin-coated microtiter plate and rendered single stranded. The two alleles are detected in two separate reactions using a singlenucleotide primer extension with radioactively labelled deoxynucleotide triphosphate (dNTP) for the variable base.
CYP3A5 was genotyped with pyrosequencing, which is a method based on the quantification of pyrophosphate release during synthesis. 41 Nucleotides are added sequentially, and the pyrophosphate released from incorporated nucleotides triggers an enzymatic reaction yielding light. As the process continues, the complementary DNA strand is built up and the nucleotide sequences differentiatng CYP3A5*3 and CYP3A5*6 from CYP3A5*1 are determined from the signal peaks in the pyrogram.
ABCB1 was genotyped by SNaPshot multiplex SNP detection. 42, 43 Multiplex PCR is used to amplify fragments for the following seven exonic SNPs: exon 1 (À12T4C), exon 2 (À1G4A), exon 11 (1199G4A), exon 12 (1236C4T), exon 21 (2677G4T/A), exon 26 (3396C4T) and the hitherto most studied polymorphism exon 26 (3435C4T). The PCR product is purified by enzymatic degradation of dNTPs and primers (1 U SAP, 2 U ExoI/reaction). Single base extension of multiple primers is performed by a cycle sequencing reaction with fluorescently labelled dideoxynucleotide triphosphates. A tail of (GACT) n is added to the primers to avoid overlap between the final SNaPshot products that are detected with an ABI 3700 capillary electrophoresis instrument, and the results are analysed using ABI Genotyper 3.7.
Statistical Analysis
Analysis of covariance was performed using the SAS software GLM. The aim was to analyse which of the studied explanatory variables have a significant effect on mean warfarin dose and mean warfarin dose per BW. To describe how the measured factors affect dose, means were adjusted for an imbalance in other variables by LS means. Adjustment for multiple comparisons was performed by the TukeyKramer method. The significance level was set at 0.05. ABCB1 haplotypes were estimated according to Phase, which is a statistical method for haplotype reconstruction from population data. 44 The association between the presence of allelic variants of the studied genes and warfarin dose/BW was investigated by dividing subjects into three equally sized groups. The distribution of allele-positive vs allele-negative subjects was compared over the three groups: low (o0.33 mg/kg), medium (0.33-0.46 mg/kg) and high (40.46 mg/kg) dose categories. Deviation from expected distribution was evaluated by w 2 , Fisher's exact and Trend tests.
In the case-control study, logistic regression and contingency tables were used to investigate whether CYP2C9, CYP3A5 and ABCB1, age, gender, interactions, indications or PT INR values were risk factors for bleeding.
